SEATTLE--(BUSINESS WIRE)--ZymoGenetics, Inc. (NASDAQ:ZGEN), will present final results from a Phase 2 clinical trial in patients with renal cell cancer at the American Society of Clinical Oncology (ASCO) annual meeting on May 31, 2009, in a poster presentation. The clinical trial evaluated Interleukin 21 (IL-21) in combination with Nexavar® (sorafenib) tablets. Abstracts are available on the ASCO website www.asco.org.
